{"DataElement":{"publicId":"3212344","version":"1","preferredName":"Prostate Carcinoma Quality-of-Life Assessment Total Score","preferredDefinition":"Numeric value to signify the total score of a person completing the Expanded Prostate Index Composite questionnaire.","longName":"EPIC_TTL_SC","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3212341","version":"1","preferredName":"Prostate Quality of Life Assessment","preferredDefinition":"A gland in the male reproductive system just below the bladder. It surrounds part of the urethra, the canal that empties the bladder. It produces a fluid that forms part of semen. (NCI-GLOSS)_The subjective measurement of an individual's sense of well-being and ability to enjoy life.  The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness._The final result of a determination of the value, significance, or extent of.","longName":"EPIC_ASSESSMT","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2527736","version":"1","preferredName":"Prostate Quality of Life","preferredDefinition":"A gland in the male reproductive system just below the bladder. It surrounds part of the urethra, the canal that empties the bladder. It produces a fluid that forms part of semen. (NCI-GLOSS):The subjective measurement of an individual's sense of well-being and ability to enjoy life.  The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness.","longName":"C12410:C17047","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Gland","conceptCode":"C12410","definition":"The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Quality of Life","conceptCode":"C17047","definition":"The subjective measurement of an individual's sense of well-being and ability to enjoy life. The concept holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1FB731E2-BF84-34A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"PWEST","dateCreated":"2006-10-13","modifiedBy":"ONEDATA","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233077","version":"1","preferredName":"Assessment","preferredDefinition":"The final result of a determination of the value, significance, or extent of.","longName":"C25367","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Assessment","conceptCode":"C25367","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F90B5E56-BAFE-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-08","modifiedBy":"ONEDATA","dateModified":"2005-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2524082","version":"1","preferredName":"Person Measure/Instrument Testing","preferredDefinition":"Process and results associated with self-reported measures and instruments, surveys, other tools","longName":"MEASURE/INSTRUMENT TESTING","context":"CCR","contextVersion":"1","origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E838B40-6636-0A25-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-09-28","modifiedBy":"REEVESD","dateModified":"2008-11-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"EPIC:Expanded Prostate Cancer Index Composite","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9FA2F667-D181-C569-E040-BB89AD436879","latestVersionIndicator":"Yes","beginDate":"2011-03-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-29","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3212343","version":"1","preferredName":"Prostate Carcinoma Quality-of-Life Assessment Total Score","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_A determination of an individual's sense of well-being and ability to enjoy life._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"EPIC_TTL_SC","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":"0","format":"9999999","PermissibleValues":[],"ConceptualDomain":{"publicId":"2524082","version":"1","preferredName":"Person Measure/Instrument Testing","preferredDefinition":"Process and results associated with self-reported measures and instruments, surveys, other tools","longName":"MEASURE/INSTRUMENT TESTING","context":"CCR","contextVersion":"1","origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E838B40-6636-0A25-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-09-28","modifiedBy":"REEVESD","dateModified":"2008-11-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3212342","version":"1","preferredName":"Prostate Carcinoma Quality-of-Life Assessment Total Score","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002:A determination of an individual's sense of well-being and ability to enjoy life.\r\n:Pertaining to an entirety or whole, also constituting the full quantity or extent; complete.:A number or range of numeric values measuring performance, function, quality, or ability.","longName":"C4863:C15584:C25304:C25338","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Quality-of-Life Assessment","conceptCode":"C15584","definition":"A determination of an individual's sense of well-being and ability to enjoy life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Total","conceptCode":"C25304","definition":"Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9FA2F667-D198-C569-E040-BB89AD436879","latestVersionIndicator":"Yes","beginDate":"2011-03-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-29","modifiedBy":"ONEDATA","dateModified":"2011-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9FA2F667-D1A9-C569-E040-BB89AD436879","latestVersionIndicator":"Yes","beginDate":"2011-03-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-29","modifiedBy":"ONEDATA","dateModified":"2011-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812571","version":"1","longName":"Lombardi Cancer Center","context":"NCIP"},{"publicId":"2812605","version":"1","longName":"Lombardi New CDEs","context":"NCIP"}]},{"publicId":"3886752","version":"1","longName":"For Review","context":"DCI","ClassificationSchemeItems":[{"publicId":"4030518","version":"1","longName":"EPIC CDEs","context":"DCI"}]}],"AlternateNames":[{"name":"DCP","type":"USED_BY","context":"DCP"}],"ReferenceDocuments":[{"name":"EPIC Total Score","type":"Preferred Question Text","description":"EPIC Total Score","url":null,"context":"NCIP"}],"origin":"EPIC:Expanded Prostate Cancer Index Composite","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9FA2F667-D1BE-C569-E040-BB89AD436879","latestVersionIndicator":"Yes","beginDate":"2011-03-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-29","modifiedBy":"REEVESD","dateModified":"2014-01-14","changeDescription":"Curated to support Lombardi Cancer Center clinical trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}